Search & fact check with cited sources for What were AstraZeneca's Q2 2026 earnings results, how did its oncology and Wainua drug pipeline perform, and what is the company's outlook toward its $80 billion 2030 revenue target?

H1 2026 cumulative performance:

• Total revenue: $30.7 billion, up 6% CER
• Core EPS: $5.21, up 11% year-over-year
• Product sales: $28.9 billion
• Alliance revenue: $1.7 billion, up 29% CER, driven by higher profit shares from partnered medicines like Enhertu
• Core gross margin: 83%
• Interim dividend: raised $0.03 to $1.06 per share

Segment drivers:

• Oncology and Rare Disease led growth, offsetting a decline in the BioPharmaceuticals segment due to generic competition
• Strong sales of cancer drugs Imfinzi and Enhertu were the primary growth engines

2026 guidance reaffirmed: The company reiterated its outlook for low double-digit core EPS growth and mid-to-high single-digit revenue growth at CER for the full year .

Oncology Pipeline Performance

AstraZeneca's oncology performance was the standout strength of the quarter, including a major pipeline milestone:

• First wholly owned ADC breakthrough: The company's wholly owned antibody-drug conjugate (ADC), sonesitatug vedotin (soniV), achieved a survival win in gastric cancer. Management estimates peak sales potential of $3–5 billion .
• Established oncology drugs: Imfinzi and Enhertu continued to drive strong demand .
• Growing pipeline breadth: AstraZeneca emphasized that its deeply diversified oncology pipeline can absorb setbacks in other areas .

Wainua Drug Setback

The Wainua (eplontersen) program suffered a significant clinical failure shortly before the earnings report:

• Trial failure: On July 9, 2026, AstraZeneca and Ionis Pharmaceuticals announced that the Phase III CARDIO-TTRansform trial in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet its primary efficacy endpoint (composite of cardiovascular mortality and recurrent CV clinical events) .
• Share impact: The failure hammered the stock and turned investor attention to the pipeline outside oncology .
• Financial impact was limited: Most analysts estimated the trial miss wiped just 2–4% from valuation models, as Wainua was not expected to become one of AstraZeneca's largest products .
• The company's message: Management used the Q2 call to argue that a deeply diversified pipeline can absorb such setbacks, pointing to the oncology ADC win as evidence .

Outlook Toward the $80 Billion 2030 Revenue Target

AstraZeneca firmly reiterated its long-term target of $80 billion in annual revenue by 2030, first set in 2024 .

• CFO confidence: CFO Aradhana Sarin stated on Bloomberg that the company is "very much on track" to reach the $80 billion sales target .
• Strategic drivers: The target relies on continued expansion in oncology, rare disease, new treatments (including weight management), and geographic growth in the U.S. and emerging markets .
• 2026 as a transitional year: Management acknowledged headwinds from loss of exclusivity on some older drugs and U.S. drug pricing regulations, but pointed to pipeline momentum and new product launches to sustain the growth trajectory .
• CEO pushback: CEO Pascal Soriot used the strong Q2 results to push back against any suggestion that the Wainua failure jeopardized the long-term revenue goal .

Bottom line: AstraZeneca beat Q2 profit expectations, its oncology franchise delivered strong growth with a landmark ADC win, and management remained confident the $80 billion 2030 target is achievable — despite the Wainua trial failure and some revenue softness.